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Introduction: Pathological bone changes differ considerably between inflammatory arthritic diseases and most
studies have focused on bone erosion. Collagen-induced arthritis (CIA) is a model for rheumatoid arthritis, which,
in addition to bone erosion, demonstrates bone formation at the time of clinical manifestations. The objective of
this study was to use this model to characterise the histological and molecular changes in bone remodelling, and
relate these to the clinical disease development.
Methods: A histological and gene expression profiling time-course study on bone remodelling in CIA was linked to
onset of clinical symptoms. Global gene expression was studied with a gene chip array system.
Results: The main histopathological changes in bone structure and inflammation occurred during the first two
weeks following the onset of clinical symptoms in the joint. Hereafter, the inflammation declined and remodelling
of formed bone dominated.
Global gene expression profiling showed simultaneous upregulation of genes related to bone changes and
inflammation in week 0 to 2 after onset of clinical disease. Furthermore, we observed time-dependent expression of
genes involved in early and late osteoblast differentiation and function, which mirrored the histopathological bone
changes. The differentially expressed genes belong to the bone morphogenetic pathway (BMP) and, in addition,
include the osteoblast markers integrin-binding sialoprotein (Ibsp), bone gamma-carboxyglutamate protein (Bglap1),
and secreted phosphoprotein 1 (Spp1). Pregnancy-associated protein A (Pappa) and periostin (Postn), differentially
expressed in the early disease phase, are proposed to participate in bone formation, and we suggest that they play
a role in early bone formation in the CIA model. Comparison to human genome-wide association studies (GWAS)
revealed differential expression of several genes associated with human arthritis.
Conclusions: In the CIA model, bone formation in the joint starts shortly after onset of clinical symptoms, which
results in bony fusion within one to two weeks. This makes it a candidate model for investigating the relationship
between inflammation and bone formation in inflammatory arthritis.Introduction
Inflammatory arthritis is characterised by joint destruc-
tion, often resulting in severe distortion of the joint archi-
tecture, and leading to impaired function of the joints.
The balance between anabolic and catabolic bone remod-
elling, however, differs between the inflammatory arthritic
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stated.(PsA), and ankylosing spondylitis (AS). While RA pri-
marily is an erosive disease, bone erosion and bone for-
mation co-exist in patients with PsA and AS [1]. Why
the bone responds differently to an inflammatory insult
is not clarified, but may be important in directing future
treatment strategies.
Collagen-induced arthritis (CIA) is a model for RA
both due to its construct validity, including autoimmune
reaction to collagen type II and MHC class II depend-
ency, and due to its face validity, that is severe bone de-
struction. Moreover, disease development ends in bony
fusion (ankylosis) of the destroyed joints, which couldtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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arthritic diseases.
Bone formation in CIA has been described as starting
two to four weeks after onset of arthritis, but mainly
playing a role in the healing state two to three months
after onset [2]. However, in a kinetic study of new bone
formation in CIA and adjuvant-induced arthritis (AIA)
in rat, periosteal proliferation was reported as early as day
3 (CIA) and day 5 (AIA) after onset of arthritis, and new
bone formation peaked at day 27 in both models [3].
Bone formation may occur directly within the mesen-
chyme (intramembranous) or via a cartilage scaffold (endo-
chondral ossification). In both processes, the extracellular
matrix (ECM) is mineralised. In particular two pathways
have been implicated in osteoblast differentiation and bone
formation: the bone morphogenetic protein (BMP) sig-
nalling pathway, of which several proteins induce ec-
topic bone formation [4], and the wingless-type (WNT)
signalling pathway [5].
With the aim to understand the molecular mecha-
nisms linking inflammation with new bone formation,
the present study was initiated to histologically charac-
terise bone remodelling in the CIA model throughout
the disease course, and to relate this to gene expression.
To minimise variation between the data and enable cor-
relation to clinical duration of arthritis, we used tarsal
joints with a clinical score of 3. By grouping the tarsal
joints according to onset and duration of symptoms, we
show that the process of bone formation runs in parallel
with the local inflammatory process in the joint, with a




Arthritis was induced in male DBA/1JBom mice by
intradermal injection of 100 μl chicken collagen type II
(CII) (2 mg/ml) (Sigma-Aldrich, St Louis, MO, USA) in
complete Freund’s adjuvant (CFA) (0.5 mg/ml) (Sigma-
Aldrich) on day 1 and boosted on day 21 with CII in in-
complete Freund’s adjuvant (IFA) (Sigma-Aldrich). The
control group received CFA and IFA without collagen,
respectively. The mice were scored for onset, severity
and duration of arthritis in the tarsal joints. Severity in
this joint was scored from 0 (no erythema or swelling)
to 3 (severe erythema and swelling). Tarsal joints were
collected for histology and gene expression analysis. The
mice were, in addition, assigned a total score for all four
paws (with a theoretical maximum of 24 points for all
paws). This additional scoring system was used to judge
when the animals should be euthanized as required by
Danish legislation (score exceeding 10 points). The mice
were housed under standard conditions, and provided pel-
lets and water ad libitum. The Danish Ethics Authorities‘The Animal Experiments Inspectorate’ approved the
studies (permit number: 2008/561 − 1532).
Histology
Fifty-two tarsal joints were collected for histology. The
tarsal joints were divided into groups according to dur-
ation of arthritis in the joint: day 0 to 3, day 4 to 7, week
1 to 2, > 2 weeks, and > 2 weeks with declining inflamma-
tion (‘declined’). In the group ‘declined’ the joints previ-
ously had a clinical score of 3 for minimum two weeks,
after which the clinical score had declined > 1 score at the
time the joint was sampled. For all other joints, the clinical
score was 3 at the sampling time. For number of joints per
time-point, see Table S2A in Additional file 1. The joints
were fixed in formalin and decalcified in 10% Na-EDTA
for two to three weeks.
Haematoxylin and eosin-stained sections were assigned
a score for bone erosion, bone formation, synovitis, ten-
dinitis, and peritendinitis. Bone remodelling was judged
by the degree of modulation of joint structure, presence of
osteoclasts (OCs) and osteoblasts (OBs), and formation of
cartilage and woven bone (Figure S1 in Additional file 2).
Synovitis, tendinitis and peritendinitis were scored by the
degree of infiltrating cells and fibrosis. All features were
scored from 0 (no pathologic changes) to 4 (severe patho-
logic changes).
RNA extraction and microarray analysis
Three tarsal joints were sampled per group (twelve joints
in total). For the group ‘More than two weeks, with de-
clined inflammation’ the joints had had a clinical score
of 3 for minimum two weeks, after which the clinical
score had declined > 1 score at the time for sampling. For
all other joints, the clinical score was 3 when sampled
(Table S2B in Additional file 1). The twelve joints were
compared to three joints from non-immunised control an-
imals. The joints were processed and analysed separately
(unpooled). Skin, visible muscle tissue and fur were re-
moved and tarsal joints collected by transverse sectioning
of the metatarsus bones and the tibia/fibula under the fur
border. This procedure ensured that all joints in the tarsus
were included in each sample. Except for the skin and
visible muscle, all other soft tissues were included in the
sample. The joints were subsequently snap-frozen in
liquid N2 and stored at −80°C. RNA was extracted using
the mirVana™ miRNA isolation kit (Ambion, Exiqon A/S,
Vedbæk Denmark), amplified and labelled using the
Pico amplification kit (Nugen Technologies, San Carlos,
CA, USA), according to the manufacturers’ instructions,
followed by hybridisation to Mouse Gene 1.0ST micro-
arrays (Affymetrix, Santa Clara, CA, USA).
The quality of the RNA was evaluated using the RNA
integrity number (RIN), and only samples with RIN >8.3
were included for further analysis.
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tion and quantile normalisation in R v.2.15 (Additional
file 3). Significance of differentially expressed genes was
assessed by analysis of variance (ANOVA), and adjusted
for multiple testing by estimating false discovery rates
(FDR). Data visualisation was performed in Qlucore Omics
Explorer v.2.2 (Qlucore AB, Lund, Sweden). The expres-
sion data are deposited in Gene Expression Omnibus [6];
accession number: Series record GSE61140).
Functional analysis and network representation of dif-
ferentially expressed genes was performed in Ingenuity
Pathway Analysis (IPA, Ingenuity™ Systems). Gene expres-
sion levels are indicated in the IPA networks as red (up-
regulated) or green (downregulated) in comparison to
non-induced controls.
The differentially regulated genes assigned to Bio Func-
tions of bone and skeleton, were used to compile a
comprehensive list of genes potentially involved in bone
remodelling in the CIA model.Quantitative PCR
For qPCR analysis of Bmp1, RNA (90 ng per reaction)
was reverse transcribed to cDNA using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems,
Carlsbad, CA, USA). qPCR was performed with TaqMan
Universal PCR Mastermix (Applied Biosystems, USA)
and primer-assays Bmp1 Mm00802225_m1 and Gapdh
Mm99999915_g1 (Applied Biosystems, USA). PCR was
initiated at 50°C for 2 minutes and 95°C for 10 minutes,
and the cycling conditions were 95°C for 15 seconds
and 60°C for 1 minute (40 cycles). For the remaining 14
genes (Table S4 in Additional file 4), qPCR analysis was
performed by AROS Applied Biotechnology A/S (Aarhus,
Denmark). cDNA was prepared from 100 ng RNA/sample
using the High Capacity cRNA Reverse Transcription kit
(Applied Biosystems, USA) and the qPCR reaction was per-
formed with TaqMan™ Universal PCR Master Mix (Applied
Biosystems, USA). Assay IDs for the specific primer/probe
sets (Life Technologies, Carlsbad, CA, USA) are listed in
Table S4 in Additional file 4. Samples were analysed as
triplicates and normalized by subtraction of the sample
mean Ct value from that of the mean Ct value of the
housekeeping gene Gapdh.Statistics
Histological scoring results were assessed using Kruskall-
Wallis test followed by a Dunn’s multiple comparisons
test. qPCR results were analysed by ANOVA, followed by
Bonferroni’s multiple comparison test, and compared
by linear regression to array results. The significance of
the correlation coefficients was tested using Student's
t-distribution. All statistical analyses were performed in
GraphPad Prism v.5 (GraphPad Software, San Diego,CA, USA), with the statistical unit being one joint from
each animal included.
Results
Development of arthritis and histopathology of CIA from
onset to decline of clinical symptoms
After immunization with chicken CII, mean onset of
arthritis was observed on day 31 ± 8.8. Mean score of
arthritis peaked six weeks after boost with a mean score
of 4.6 ± 1.8. In order to study local arthritis develop-
ment, onset and severity of arthritis in the tarsal joint
was recorded in detail.
For the histological study, a total of 52 tarsal joints
were used. Fourteen were sampled between day 0 and 4,
ten between day 4 and 7, eleven between week 1 and 2,
and seventeen after week 2 of clinical inflammation
onset. After week 2, twelve samples showed declining
clinical symptoms. Little variation in the appearance of
synovitis, peritendinitis, and bone remodelling was noted
within the groups. The data are in accordance with a
previously published study showing occurrence of bony
spur formation early after disease onset [3].
Day 0 to 4 after clinical disease onset: The infiltra-
tion of inflammatory cells was equally pronounced when
comparing the synovium (mean score 3.8 +/−0.4) and
the peritendon (mean score 3.9+/−0.3) (Figure 1A). In
10/14 joints, fibroblast activity and fibrosis indicated
chronic inflammation, while 4/14 joints had no signs of
chronicity. Bone pathology was dominated by erosion
(11/14 joints), initiated where the peritendon and syno-
vium are attached to, or in close proximity to the bone,
while the articular cartilage remained intact. Bone erosion
was severe as judged by the presence of multinucleated
osteoclasts (OC) and the extent of structural damage of
the cartilage and bone tissue (Figure 1B). However, both
OB proliferation, and collagen deposition, was observed in
the periosteum and seemed, from visible staining ability,
to have progressed into secretion of osteoid-like matrix in
3/14 joints (Figure 1C).
Day 4 to 7 after clinical disease onset: Severe fibro-
sis and synovitis approaching the articular cartilage,
and resulting in erosion of the articular cartilage, was
observed (Figure 1D). In areas of less severe inflammation,
pronounced OB activity and onset of endochondral ossifi-
cation was noted as judged from the appearance of hyper-
trophic cartilage. Bone erosion (mean score of 3.1+/−1.3)
and bone formation (2.2+/−1.1), was observed in 9/10
joints.
Week 1 to 2 after clinical disease onset: Bone erosion
(score 2.6+/−1.4) and bone formation (score 2.9+/−1.1)
was pronounced and observed in 10/11 joints. Endo-
chondral ossification was dominating (Figure 2A). An-
kylosis was noted from day 8 and consisted of an inner




Figure 1 Histopathology of tarsal joints day 0 to 7. A) Day 0 to 4: overview of inflammation in the tarsal joint showing equal severity of
inflammation in peripheral tissues and synovium (arrows). (B-C) Day 0 to 4: bone erosion and OC activity (arrow in B, day 3) dominates.
Proliferation and collagen deposition takes place (star in C, day 0) in the periosteum and results in osteoid deposition (arrows in C, day 3).
(D) Day 4 to 7: the joint architecture is severely distorted (day 7). OC, osteoclast.
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sisted of mesenchymal cells (Figure 2B). In most joints,
inflammation was severe, but gradually disappearing
and replaced by severe fibrosis with yet active fibroblast
proliferation.
Two weeks after clinical disease onset: The clinical
severity of inflammation was declining in most joints, al-
though 5/17 joints still showed severe clinical signs. In
the joints with severe clinical arthritis, accumulation of
cartilage was still apparent, while in joints with declining
clinical symptoms, an increase in what was observed as
mineralisation of cartilage and newly formed bone tookplace, in addition to modification of the newly formed
bone by OCs (Figure 2C).
By comparing the development in scores for bone erosion
and bone formation, respectively, a significant difference
over time was observed with the greatest development
in scores of bone formation (P = 0.0186 vs. P <0.0001)
(Figure 2D).
Gene expression in joints from mice with CIA normalises
after two weeks of inflammation
Having examined the bone remodelling after clinical on-




Figure 2 Histopathology of tarsal joints from day 8 and until decline of symptoms. (A) Appearance of cartilage (encircled) marks the onset
of endochondral ossification (day 8). (B) Ankylosis has progressed from being fibrous to consist of cartilage and osteoid (day 10), with osteoid
closest to the original bone (arrow). (C) Declining disease phase: bone formation is remodelled with OC activity observed in some animals
(arrow). (D) Histological scores of bone erosion (black bars) and bone formation (grey bars) over time (mean +/− standard deviation (SD)).
Statistics from the comparisons of individual groups is indicated by lines above the bars (Dunn’s multiple comparison test, *P <0.05, **P <0.01,
***P <0.001). OC, osteoclast.
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sion profiling (Figure 3A and B).
Unsupervised hierarchical clustering grouped the sam-
ples into a phase of high transcriptional activity between
week 0 and 2, and, subsequently, a period of declining
transcriptional activity. One sample from the declining
disease phase (decline 10) clustered together with the
controls, showing that the gene expression pattern nor-
malised in the late disease phase (Figure 3A). In the firstthree days, 908 genes displayed a +2-fold change in the
transcriptional level, while 749 genes were differentially
expressed in week 1 to 2 (>2 fold change, P <0.05). The
IPA showed that the top biological functions, canonical
pathways, and upregulated genes were dominated by
genes involved in arthritis and the immune system in
general, in connective and skeletal tissue disorders and
remodelling, as well as tissue development and function








Figure 3 Cluster analysis and validation of gene expression profile. (A) Separation of samples by unsupervised hierarchical clustering. The
groups are: day 0 to 3, week 1 to 2 and week 3 to 4 after onset of arthritis, and joints with declining clinical disease activity. Colours and colour
intensity indicate upregulation (red) or downregulation (green) regulation of genes. (B) Venn diagram of the gene expression study showing
the number of genes differentially expressed at the time points: day 0 to 3, week 1 to 2, week 3 to 4, and in the declining disease phase in
comparison to control. (C) The results from the microarray study were validated with qPCR. Bmp1 was normalised to Gapdh expression and
compared to a control sample from non-immunised mice. Statistically significant differences between group means (δ-ct-values) are indicated
with lines above the bars (Bonferroni’s multiple comparison test, *P <0.05, **P <0.01). (D) The gene expression level of Bmp1 assessed by qPCR
correlated significantly (r2 = 0.7, P <0.0002) with the corresponding microarray data (linear regression test).
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Postn, Ctsk, Mmp3 and Mmp13) demonstrated very high
fold changes (between 10.6 and 45.3) (Table 1). Moreover,
pregnancy–associated plasma protein A (Pappa) was
strongly upregulated when comparing day 0 to 3 with
week 1 to 2 (fold change +2.3) (Table 2). A muscle- and
epidermis-specific gene expression signature was foundamong the most downregulated genes when comparing
day 0 to 3 and control samples (Table 1).
In week 3 to 4 after onset of disease, the number of
two-fold differentially expressed genes had decreased to
353 (Figure 3B). The pathway profile changed accord-
ingly, and was dominated by tissue remodelling and
developmental pathways, although an inflammatory gene
Table 1 Highly differentially expressed genes grouped according to function
Gene symbol Ctrl (Log2AFU)
a Day 0 to 3b week 1 to 2c Week 3 to 4d Declinee Localisation Ar vs. Nf Ar vs. Ng
Saa3 6.8 44.1 26.2 7.8 2.7 Plasma 18.0 2.0
Mmp3 7.2 23.1 11.9 5.2 2.9 Synovium 10.1 5.3
Mmp13 7.6 13.2 17.3 8.9 4.5 Synovium 3.5 2.3
Timp1 7.5 19.4 9.3 5.3 3.4 Synovium 1.9 3.5
Ctsk 7.8 11.0 11.7 7.6 4.8 Osteoclasts 2.8 1.7
Atp6v0d2 6.97 9.03 7.18 5.94 3.67 Endosome 1.5 1.0
Postn 8.5 10.3 9.8 5.0 2.5 Osteoblasts 4.5 1.0
Krtdap 7.6 0.1 0.2 4.5 14.1 Skin* 0.4 1.1
Lce1a1/1a2 8.2 0.1 0.1 2.8 7.9 Skin NA 1.0
Lor 8.4 0.1 0.2 3.7 5.4 Skin* 0.6 1.1
Krt1/2/5/14 7.8 0.1 0.2 3.4 10.3 Skin* 0.8 1.0
Mt4 7.40 0.32 0.36 4.63 19.15 Epithelia* 0.8 1.0
Myl2 10.5 0.1 0.8 1.0 1.0 Muscle 0.2 0.6
Pygm 10.8 0.1 0.4 0.4 0.6 Muscle 0.5 0.7
Casq1 10.78 0.12 0.85 0.57 0.72 Muscle 0.5 0.7
Myh4 11.96 0.13 0.45 0.31 0.43 Muscle 0.3 0.9
Ckm 10.78 0.14 0.44 0.46 0.76 Muscle 0.6 0.7
aMean log2 expression in non-induced control mice. Mean fold change in comparison to control: bon day 0 to 3, cin week 1 to 2, din week 3 to 4, ein the declining
disease phase. Fold change of gene expression in arthritic joints from the fTNFα overexpressing model versus control [7], and the gPGIA arthritis model versus
control [8], *Differentially expressed epidermal specific genes in arthritic joints from the present study and the TNFα overexpressing model [7]. Ctrl, control; PGIA,
proteoglycan-induced arthritis; TNFα, tumour necrosis factor alpha.
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in Additional file 5).
A comparison of gene expression between week 0 to 2
and week 3 to 4 revealed considerable up-regulation of
several epidermal genes (fold changes between 3.8 and
13.9) in the samples collected three to four weeks after
onset of arthritis (Table 1).
The expression pattern of 15 differentially expressed
genes was verified by qPCR. Of these, 12 genes corre-
lated significantly with the gene expression pattern ob-
tained from the microarray profile, while three genes
showed the same expression pattern, but the correl-
ation was not significant. The expression of Bmp1 is
shown in Figure 3C and D (r2 = 0.7, p < 0.0002), and the
remaining validation data are shown in Figure S6 in
Additional file 6 and Figure S7 in Additional file 7 and
with the corresponding r2 and P-values in Table S8 in
Additional file 8.
To identify genes associated with the observed bone
pathology, we focused on genes, differentially expressed
at the different time-points, which were related to bone
and skeleton in the IPA Bio Functions. The genes and
associated Bio Functions reflected the bone remodelling
process (Table S9 in Additional file 9), and their number
and effect size declined over time. The genes and their
expression profiles are shown individually in Table S10
in Additional file 10.Distinctive expression profiles of genes involved in
osteoblast and osteoclast functions
The differentially expressed genes, related to bone, from
Table S10 in Additional file 10, were divided into profiles
and are shown separately in Table 2. Profile one encom-
passed genes with the highest expression on day 0 to 3
with a subsequently declining profile. These were in par-
ticular genes encoding proteins involved in OC differen-
tiation and function (Ccl9, Tyrobp, Atp6v0d2, Lif; fold
changes between 2.0 and 9.2), in addition to ECM for-
mation and collagen type 1 assembly (Bmp1, Crtap, Tnc,
Lox; fold changes between 1.9 and 10.6) [9-14] (Table 2,
Figure 4A, and Table S10 in Additional file 10). In pro-
file two, genes with the highest expression in week 1 to
2, followed by a declining expression pattern, were in-
cluded. These were in particular genes encoding pro-
teins involved in mineralisation and osteoblast function
(Sp7, Spp1, Mgp, Sparc, Enpp1, Bglap1, Ifitm5; fold
changes between 1.5 and 4.5) [15-21] (Table 2, Figure 4B
and Table S10 in Additional file 10). Integrin-binding
sialoprotein (Ibsp; fold change +3.0) also belongs to this
group [20], but showed the highest expression in week 3
to 4. Moreover, a large group of genes showed a sus-
tained differential expression pattern at day 0 to 3 and
week 1 to 2. These included genes involved in osteoblast
functions and ECM formation (Col1a1, Col1a2, Ogn,
Bgn, Col12a1, Ppib, Lum, Hapln1, Cthrc1, Postn; fold
Table 2 Groups of genes showing a time-dependent expression pattern
Gene symbol Ctrla Day 0 to 3b Week 1 to 2c Week 3 to 4d Declinee
Log2 Fold change (P-value) Protein function in relation to bone
Osteoclast function: highest differential expression day 0 to 3
Ccl9 6.42 2.05 (0.01) 1.78 (0.01) 1.61 (0.10) 1.44 (0.10) Stimulates OC motility and polarisation through CCR1.
Tyrobp 10.21 4.09 (0.03) 3.31 (0.02) 2.47 (0.06) 1.56 (0.33) Kinase involved in the generation of the actin
cytoskeleton in OC, which is critical for bone resorption.
Atp6v0d2 6.97 9.03 (0.01) 7.18 (0.003) 5.94 (0.005) 3.67 (0.02) ATPase proton pump involved in acidification of the
extracellular resorption lacuna created by OC and early
OC differentiation.
Lif 5.74 2.20 (0.01) 1.12 (0.22) 0.85 (0.39) 0.73 (0.10) Expressed in OC and modulates the recruitment of OB
to resorption surfaces in a TGFβ dependent manner.
Early osteoblast function: highest differentially expression day 0 to 3
Bmp1 7.52 1.86 (0.07) 1.67 (0.10) 1.52 (0.13) 1.28 (0.30) Metalloproteinase that may play a role on several levels
of bone formation. It processes the c-terminal end of
pro-collagen type I, activates other BMPs and processes
BGN and DMP1. Expressed in patients with arthritis and
acute fractures.
Crtap 6.84 2.69 (0.02) 2.43 (0.01) 1.66 (0.12) 1.12 (0.77) Scaffolding protein that associates with others to
hydroxylate collagen type I chains. Associated with
osteogenesis imperfecta.
Tnc 9.19 3.01 (0.03) 2.67 (0.03) 2.09 (0.05) 1.72 (0.11) Pro-inflammatory extracellular matrix protein, expressed
in synovium and blood in RA patients. Involved in
extracellular matrix remodelling, where it is bound by
periostin.
Lox 7.13 4.51 (0.11) 3.52 (0.14) 2.49 (0.23) 1.57 (0.49) Catalyses cross-linking of collagen type I. Is activated
by BMP1.
Late osteoblast function: highest differentially expression week 1 to 2 or week 3 to 4
Sp7 6.43 1.02 (0.90) 1.67 (0.04) 1.19 (0.25) 1.01 (0.95) Transcription factor with a critical role in osteoblast
differentiation.
Spp1 8.37 2.90 (0.05) 4.46 (0.00003) 3.49 (0.003) 1.98 (0.14) OB marker, expressed in OB, OC, and osteocytes.
Inhibits formation and growth of hydroxyapatite by
binding the crystals. Promotes attachment of OC to
bone under control of Acp5 phosphatase.
Mgp 10.45 2.61 (0.06) 3.33 (0.04) 2.45 (0.07) 1.65 (0.21) Inhibitor of bone mineralisation.
Sparc 11.77 2.17 (0.04) 2.48 (0.03) 2.13 (0.04) 1.68 (0.07) The protein binds hydroxyapatite when bound to
collagen type I in vitro. Sparc null mice have normal
collagen content in bone, but reduced bone formation
and numbers of OC and OB.
Enpp1 9.08 2.72 (0.01) 3.19 (0.0003) 2.52 (0.01) 1.60 (0.15) Expression is induced in OB by MDK. Essential for
converting extracellular ATP to inorganic
pyrophosphate, thus controlling the levels and
functions in bone mineralization and soft tissue
calcification. Essential for normal bone development.
Bglap1 9.05 0.75 (0.62) 2.63 (0.0004) 1.82 (0.04) 1.37 (0.13) OB marker and serum marker of bone formation.
Expressed in the late mineralisation phase. The exact
role of the protein in bone is, however, debated as
data is controversial.
Ifitm5 6.67 1.25 (0.11) 1.47 (0.03) 1.35 (0.05) 1.14 (0.27) Expressed in OB and involved in mineralisation.
Ibsp 10.67 2.22 (0.02) 2.59 (0.01) 2.99 (0.01) 2.19 (0.02) Marker of late OB differentiation. Expressed in OB, OC,
hypertrophic chondrocytes and osteocytes. Binds to the
AvB3 integrin and hydroxyapatite, probably mediating
cell attachment to matrix. Nucleates hydroxyapatite.
Sustained high expression week 0 to 2
Col1a2 9.94 1.88 (0.08) 2.25 (0.05) 2.03 (0.06) 1.69 (0.10) This gene encodes the alpha2 chain of collagen type I.
Collagen type I is the most abundant protein in bone
and a marker of OB activity.
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Table 2 Groups of genes showing a time-dependent expression pattern (Continued)
Col1a1 9.84 1.80 (0.11) 2.25 (0.05) 1.92 (0.09) 1.69 (0.14) This gene encodes the alpha1 chain of collagen type I.
Collagen type I is the most abundant protein in bone
and a marker of OB activity.
Ogn 7.83 2.28 (0.07) 3.88 (0.02) 2.16 (0.09) 1.43 (0.34) Proteoglycan belonging to the SLRP family. The protein
is processed by BMP1 and regulates collagen type I
fibrillogenesis.
Bgn 10.63 2.18 (0.04) 2.21 (0.03) 1.63 (0.09) 1.08 (0.72) Proteoglycan belonging to the SLRP family. KO mice
have reduced collagen synthesis, reduced bone mass
and production of bone precursor cells. The protein is
processed by BMP1.
Col12a1 8.24 4.59 (0.04) 4.81 (0.04) 2.98 (0.08) 1.75 (0.25) Expressed by OB in areas of bone formation. COL12A1
KO mice have skeletal abnormalities with less
mechanical strength and reduced matrix deposition.
Ppib 7.45 2.17 (0.04) 2.27 (0.07) 1.49 (0.14) 1.16 (0.64) Associates with other proteins to hydroxylate collagen
type I chains. Associated with osteogenesis imperfecta.
Lum 10.18 3.37 (0.04) 3.97 (0.03) 2.78 (0.05) 1.69 (0.18) Proteoglycan belonging to the SLRP family (same as
BGN).
Hapln1 6.72 1.69 (0.15) 3.10 (0.01) 2.88 (0.005) 2.08 (0.01) Involved in cartilage biosynthesis by linking aggrecans
and hyalyron acid. Polymorphism in this gene is
associated with osteophyte formation in osteoarthritis
and it is located in a susceptibility locus of AS.
Postn 8.52 10.33 (0.07) 9.76 (0.07) 4.97 (0.12) 2.53 (0.29) Promotes cell survival of preosteoblasts and OB.
Increases activation of pro-lysyl oxidase, which
cross-links collagen type I.
Cthrc1 8.46 4.78 (0.06) 6.79 (0.05) 3.50 (0.10) 1.65 (0.43) Molecule that stimulates bone formation, secreted
by OC.
Others
Igf1 9.68 1.94 (0.04) 2.61 (0.03) 1.82 (0.05) 1.18 (0.59) Growth factor positively regulating bone formation.
Regulates bone mineral density.
Pappa 5.99 2.24 (0.0002) 1.20 (0.06) 1.08 (0.11) 0.96 (0.68) IGF-dependent proteinase that regulates the
bioavailability of IGF. Expressed in fibroblasts,
chondrocytes and OB. Pappa KO mice have reduced
bone formation and delayed fracture-healing.
Dmp1 8.30 0.74 (0.42) 1.2 (0.59) 1.81 (0.17) 1.47 (0.30) Extracellular matrix protein that is processed by BMP1
and involved in mineralisation of extracellular matrix.
Expressed by hypertrophic chondrocytes, osteocytes,
and OB.
Tissue degradation
Mmp13 7.57 13.15 (0.02) 17.33 (0.02) 8.93 (0.02) 4.53 (0.05) Bone resorption, OC- and osteoprogenitor
differentiation.
Ctsk 7.82 11.02 (0.04) 11.75 (0.04) 7.58 (0.04) 4.80 (0.08) Bone resorption. Principle enzyme degrading osteoid.
Mmp3 7.24 23.11 (0.02) 11.87 (0.01) 5.24 (0.04) 2.94 (0.11) Metalloproteinase associated with arthritis.
Timp1 7.53 19.45 (0.002) 9.33 (0.001) 5.30 (0.03) 3.44 (0.02) Inhibitor of metalloproteinases.
Mmp9 7.15 4.24 (0.02) 3.79 (0.02) 2.95 (0.04) 2.20 (0.08) Resorption, OC- and osteoprogenitor differentiation.
Ctss 8.32 3.62 (0.04) 2.99 (0.05) 2.29 (0.08) 1.68 (0.20) Expressed in hypertrophic chondrocytes and OC.
Mmp19 5.99 2.18 (0.02) 2.05 (0.01) 1.45 (0.16) 1.26 (0.09) Degradation of extracellular tissue.
Mmp14 7.92 2.63 (0.02) 2.82 (0.02) 2.11 (0.02) 1.77 (0.05) Involved in tissue destruction in RA.
Acp5 7.30 3.68 (0.02) 3.46 (0.03) 3.59 (0.03) 2.50 (0.03) The encoded protein is a phosphatase, also called Trap.
It is a marker of OC function and is extensively
expressed in OC. It is activated by Cathepsin K and
dephosphorylates SPP1 and IBSP. Plays an inhibitory
role in collagen type I synthesis, degradation, and
mineralisation.
Genes of the BMP pathway
Bmp2 7.16 1.67 (0.30) 1.68 (0.29) 1.24 (0.63) 1.26 (0.59) Ligand of the BMP pathway.
Bmpr1a 6.88 1.84 (0.13) 2.01 (0.10) 1.91 (0.11) 1.15 (0.72) Type I receptor of the BMP pathway.
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Table 2 Groups of genes showing a time-dependent expression pattern (Continued)
Bmpr2 8.36 2.05 (0.04) 1.65 (0.08) 1.40 (0.15) 1.30 (0.28) Receptor type II in the BMP pathway.
Smad2 7.23 2.05 (0.14) 2.14 (0.12) 1.70 (0.22) 1.44 (0.37) Regulatory Smad involved in BMP signalling.
Smad6 7.27 0.55 (0.08) 0.58 (0.0045) 0.72 (0.04) 0.76 (0.12) Inhibitory Smad antagonising BMP signalling.
Smad4 8.16 1.28 (0.18) 1.27 (0.19) 1.18 (0.32) 1.04 (0.84) Co-Smad associating with regulatory Smads.
Smad5 7.07 1.40 (0.04) 1.28 (0.06) 1.20 (0.17) 0.99 (0.92) Regulatory Smad involved in BMP signalling.
Bmp4 7.68 0.59 (0.04) 0.68 (0.04) 0.99 (0.95) 0.95 (0.61) Ligand of the BMP pathway.
Bmp6 8.44 0.62 (0.07) 0.75 (0.15) 0.88 (0.67) 0.93 (0.63) Ligand of the BMP pathway.
Bmp7 5.82 0.78 (0.19) 0.86 (0.31) 0.94 (0.67) 1.26 (0.17) Ligand of the BMP pathway.
Inhba 7.20 5.65 (0.01) 3.94 (0.01) 2.09 (0.07) 1.17 (0.77) Non-steroidal hormone reported to increase bone
formation in transgenic mice overexpressing human
inhibin A. Associated with human arthritis.
Acvr2a 7.23 1.27 (0.33) 1.29 (0.03) 1.18 (0.04) 0.91 (0.34) Type II receptor of the TGFβ pathway.
Acvr2b 6.21 0.80 (0.01) 0.73 (0.0034) 0.76 (0.03) 0.85 (0.29) Type II receptor of the TGFβ pathway.
Genes of the WNT pathway
Fzd1 6.91 1.70 (0.05) 1.57 (0.05) 1.39 (0.08) 1.18 (0.37) Receptor of the WNT pathway.
Hif1a 8.35 4.23 (0.02) 3.56 (0.02) 2.49 (0.03) 1.43 (0.34) Regulates the cellular response to hypoxia during
endochondral bone formation and inhibits WNT
signalling in OB in cooperation with Sp7.
Sost 7.28 0.48 (0.03) 0.61 (0.02) 0.62 (0.03) 0.73 (0.15) WNT antagonist and marker of mature osteocytes.
Ndrg2 10.56 0.18 (0.01) 0.31 (0.0014) 0.37 (0.01) 0.52 (0.01) Down-regulates WNT-signalling mediated TCF-
promotor activity and GSK3β phosphorylation
synergistically with PRA1.
Dkk1 7.19 0.67 (0.18) 0.85 (0.25) 1.15 (0.32) 1.09 (0.43) Antagonist of the WNT pathway.
Tcf4 7.96 1.46 (0.09) 1.73 (0.03) 1.30 (0.28) 0.99 (0.94) Transcription factor of the WNT pathway.
aMean log2 expression in non-induced control mice. Mean fold change and p-value in comparison to control: bon day 0 to 3, cin week 1 to 2, din week 3 to 4, ein
the declining disease phase. The highest differential expression value and corresponding p-value of each gene are shown in bold italics. AS, ankylosing spondylitis;
BMP, bone morphogenetic protein; BGN, biglycan; CCR1, C-C chemokine receptor type 1; Ctrl, control; DMP1, dentin matrix acidic phosphoprotein1; IGF, insulin-like
growth factor; KO, knockout; MDK, midkine; OB, osteoblast; OC, osteoclast; RA, rheumatoid arthritis; SLRP, leucine rich repeat containing 6; TCF, T-cell-specific
transcription factor; TGFβ, transforming growth factor beta.
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nally, tissue destruction was reflected by up-regulation of
the genes for four metalloproteinases (MMPs): the MMP
inhibitor Timp1; acid phosphatase 5 (Acp5); cathepsin K
[28]; cathepsin S [29], and additional cathepsins. These
genes were among the most highly expressed, throughout
disease development (Table 1, Table 2 and Table S10 in
Additional file 10).
Differential expression of genes belonging to the BMP
pathway
Differentially expressed genes related to the BMP pathway
included the genes encoding the BMP type I and type II
receptors (Bmpr1a and Bmpr2, fold change +2 at week 1
to 2 and day 0 to 3, respectively), and proteins down-
stream of the BMP signalling pathway (Smad2 and Smad6,
fold change +2.1 at week 1 to 2 and −1.8 at day 0 to 3, re-
spectively) (Table 2, Figure 5 and Table S10 in Additional
file 10). The BMP ligand Bmp2 (fold change +1.7 at day 0
to 3) together with Smad4 (fold change +1.3 at day 0 to 3)
and Smad5 (fold change +1.4 at day 0 to 3) showed thesame marginal change in expression pattern. The BMP
ligands Bmp4, Bmp6, and Bmp7 were slightly downreg-
ulated (fold change between −1.7 to −1.3 at day 0 to 3).
High upregulation of the gene for Inhibin beta A (Inhba;
fold change +5.6 at day 0 to 3) was found, in addition to
minor expression changes in the genes of some of the
transforming growth factor beta (TGFβ) receptors (Acvr2a
and Acvr2b) bound by this protein (Table 2 and Figure 5A).
Differential expression of genes belonging to the WNT
pathway
Within the group of genes related to the WNT pathway,
the genes for the receptor FZD1 (fold change +1.7 at day
0 to 3) and transcription factor TCF4 (fold change +1.7
at week 1 to 2) were differentially expressed, in addition
to a number of WNT inhibitors. These included the
hypoxia-induced Hif1a, which showed more than 4-fold
up-regulation and Sost and Ndrg2, which were between
2 and 5.6-fold downregulated. The well-described WNT
inhibitor Dkk1 was slightly downregulated (Table 2 and
Table S10 in Additional file 10).
AB
Figure 4 (See legend on next page.)
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Figure 4 Gene expression networks during osteoblast activity in early and late phases of joint inflammation. A) A network of genes
related to osteoblast activity, in particular collagen type I assembly and cross-linking, during the early phase of clinical disease. Colours and colour
intensity indicate upregulation (red) or downregulation (green) regulation of genes at day 0 to 3, where most of the genes showed the greatest
fold change in comparison to non-induced controls. One exception is Dmp1, which became upregulated at week 3 to 4. B) A network of genes
related to osteoblast activity, in particular mineralisation, during the late phase of clinical disease. Colours and colour intensity indicate upregulation
(red) or downregulation (green) regulation of genes at week 1 to 2, where most of the genes showed the greatest fold change in comparison to
non-induced controls. One exception is Ibsp, which was most highly upregulated in week 3 to 4.
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human arthritis
Some of the genes differentially expressed in the herein
presented study have been linked to human arthritis in
genome-wide association studies (GWAS) (Table 2). Of
those genes, several are involved in cartilage- and bone
remodelling (underlined in Table 3).
Discussion
In this study, we have shown that in CIA, major histo-
pathological changes, comprising inflammation as well
as bone formation and ankylosis, occur within the first
two weeks after the inflammatory symptoms become
clinically apparent in a joint. Moreover, we have shown
that the histopathology is reflected at the gene expres-
sion level, where a number of genes, coding for proteins
important in inflammation and bone remodelling, are
differentially expressed within the same time period after
disease onset. This suggests that the CIA model is rele-
vant for the osteoproliferative inflammatory arthritis in
PsA and AS.
Bone formation in the murine CIA model has been de-
scribed as starting in the subacute inflammatory disease
phase, two to four weeks after onset of arthritis, but
mainly playing a role in the healing state two to three
months after onset [2]. However, no studies disclose any
molecular details regarding bone formation throughout
the arthritis disease course. Recently, Schett et al. [3]
performed a histological study of new bone formation in
the rat CIA and AIA models. In their study, periosteal
proliferation was noted on day 3 (CIA) and day 5 (AIA)
after onset of arthritis and new bone formation peaked
at day 27 after onset of arthritis in both models.
The link between joint inflammation and bone remod-
elling is not clear. In human arthritis, areas with inflam-
mation were shown to be predictive of bone formation
[42], but bone formation does not seem to be blocked by
anti-tumor necrosis factor alpha (TNFα) treatment [43].
In the present study, we have shown that in the murine
CIA model, bone formation is (1) initiated during active
inflammation, (2) develops in parallel with the inflam-
mation, and (3) that the bone mineralises and remodels
when clinical inflammatory signs are declining.
The molecular events underlying inflammation and
bone remodelling were investigated using gene expressionprofiling. The results are based on a first kinetic mapping
of global gene expression in the joint during clinical onset
and development of arthritis. Expression of specific genes
might differ depending on the microanatomical site within
the joint and future studies of proteins important in the
interplay between inflammation and bone formation
should address this. We found that the bone pathology
observed histologically was reflected in the Bio Functions,
significantly associated with differentially expressed genes,
from onset to decline of clinical arthritis in the joint.
Moreover, genes involved in inflammation and bone re-
modelling were co-expressed during the first two weeks
after onset of clinical arthritis and, hereafter, the gene
expression gradually normalized to control levels, while
the clinical inflammation was declining. A muscle-specific
signature was observed among the most downregulated
genes during the first two weeks after onset of arthritis.
This may reflect muscle inactivity and atrophy observed
in the model [44] and may translate to the impaired
muscle function observed in arthritis patients. However,
since animals in the acute disease phase also lose weight,
this may partly explain some of the gene expression
changes observed in muscle-specific genes.
Several metalloproteinases and cathepsins associated
with human arthritis showed sustained, high expression
during the entire disease course (Table 1, and Table S10
in Additional file 10). These reflect tissue destruction, in
addition to being a link between bone erosion and bone
formation. MMP9 and MMP13 have been shown to play
a crucial role in endochondral bone formation, as well as
in matrix degradation and in OC and osteoprogenitor
differentiation [45,46].
Genes with the highest fold change at day 0 to 3 after
onset of clinical arthritis reflected osteoclast function
and differentiation, in addition to ECM formation and
collagen type 1 assembly, while genes showing the highest
fold change at week 1 to 2 or week 3 to 4 encompassed a
well-known group of OB markers and genes involved in
mineralisation (Table 2, Figure 4A and B). These varia-
tions in gene expression pattern mirror the development
in OB differentiation and function, as gene expression is
specific for the differential stages of the OB [47]. The gene
expression profiles followed the histological observations:
bone erosion, periosteal proliferation and osteoid secre-
tion, was observed in the initial phase followed by onset of
AB
Figure 5 Differentially expressed genes related to BMP signalling at day 0 to 3 of arthritis in comparison to non-induced controls.
Regulation of genes is indicated by colour and colour intensity (red = upregulated, green = downregulated). (A) Network of BMP related genes
in general. (B) Functional pathway of BMP signalling. BMP, bone morphogenetic protein.
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Table 3 Differential expression of genes associated with human arthritis in GWAS studies









log2 Fold change (P-value)
Ankylosing spondylitis
Hapln1 6.72 1.69 (0.15) 3.10 (0.01) 2.89 (0.005) 2.08 (0.01) Involved in cartilage development and bone formation.
Associated with osteophyte formation in OA [30].
Edil3 5.58 1.53 (0.14) 2.95 (0.003) 3.07 (0.005) 2.33 (0.11) Integrin ligand with a proposed role in cartilage
development and angiogenesis. Inhibitor of the WNT
pathway [30].
Ano6 7.22 2.25 (0.05) 1.88 (0.04) 1.61 (0.14) 1.19 (0.60) Regulates phosphatidylserine exposure on the cell
surface, which is essential for mineralisation of bone
and involved in osteoclast formation [30,31].
Psmg1 6.95 2.04 (0.002) 1.91 (0.002) 1.37 (0.03) 1.03 (0.78) Proteasome Assembly Chaperone 1. The gene is, in addition,
associated with inflammatory bowel disease [32].
Rheumatoid arthritis
Anapc4 6.85 1.77 (0.0008) 1.91 (0.0003) 1.45 (0.02) 1.18 (0.45) An SNP close to this gene was associated with RA
susceptibility [33]. The encoded protein is an E3 ubiquitin
ligase involved in control of the cell cycle, muscle cell
function, and function of neurons [34].
Cd84 5.61 3.07 (0.01) 3.01 (0.004) 2.17 (0.02) 1.51 (0.12) Membrane protein involved in immune function. High
expression of the gene was associated with a positive
response to Etanercept treatment [35].
Il6st 9.44 2.41 (0.03) 1.79 (0.06) 1.52 (0.10) 1.09 (0.76) Signal transducing subunit for cytokines belonging to
the IL-6 family. Activates Stat-3, which plays a role in OC
and OB differentiation and their interaction [36].
Ptpn2 6.68 1.74 (0.06) 1.78 (0.02) 1.32 (0.30) 1.46 (0.16) Protein phosphatase involved in T-cell activation by
regulation of the JAK/STAT signalling pathway [33,37,38].
Cdk6 5.88 2.51 (0.10) 2.35 (0.08) 2.11 (0.08) 1.64 (0.21) Cyclin-dependent kinase involved in proliferation of
lymphocytes [39].
Prkcq 7.42 0.48 (0.17) 0.65 (0.26) 0.55 (0.16) 0.61 (0.32) Kinase involved in activation of NFκB and AP-1 transcription
factors [39].
Prkch 7.20 1.36 (0.04) 1.43 (0.07) 1.58 (0.06) 0.99 (0.95) Serine/threonine kinase. The association with RA is
suggestive [38].
Osteoarthritis
Gnl3 7.81 2.41 (0.11) 2.10 (0.08) 2.17 (0.07) 1.47 (0.34) Nucleostemin. Increased in in vitro cultures of chondrocytes
from patients with OA [40].
Glt8d 7.18 1.97 (0.03) 1.99 (0.02) 1.43 (0.05) 1.13 (0.71) Involved in glycosylation of cartilage proteins [40].
Pla2g 5.96 1.47 (0.16) 1.67 (0.04) 2.06 (0.03) 1.71 (0.04) Cytosolic phospholipase A2 enzyme. mRNA transcript was
abundantly expressed in chondrocytes from OA patients [41].
Ptgs2 6.91 2.66 (0.01) 1.72 (0.07) 1.15 (0.41) 1.56 (0.03) Cyclooxygenase 2 (COX-2). mRNA transcript was abundantly
expressed in chondrocytes from OA patients [41].
Col12a1 8.24 4.56 (0.04) 4.82 (0.01) 2.97 (0.04) 1.74 (0.22) A SNP close to this gene has been associated with OA
susceptibility [40]. The encoded protein is expressed by
OB in areas of bone formation. KO mice have skeletal
abnormalities with less mechanical strength and
reduced matrix deposition [24].
aMean log2 expression in non-induced control mice. Mean fold change and P-value in comparison to control: bon day 0 to 3, cin week 1 to 2, din week 3 to 4, ein
the declining disease phase. Genes shown in bold are encoding proteins with a known function in cartilage- or bone remodelling. Ctrl, control; GWAS, genome-wide
association studies; IL-6, interleukin 6; KO, knockout; NFκB, nuclear factor kappa B; OA, osteoarthritis; OB, osteoblast; OC, osteoclast; RA, rheumatoid arthritis;
WNT, wingless-type.
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1 to 2. The data support a model for bone remodelling
during arthritis, where bone erosion is mainly taking place
during the very early phase of clinical arthritis, with the
onset of tissue remodelling and bone formation following
shortly after, developing in parallel with the inflammation.When the inflammatory response ceases, the addition of
new bone decreases, and the hitherto created bone is
remodelled and mineralised. As suggested by the histo-
logical results, the newly formed bone may be created in
different processes depending on the microanatomical
site. Thus, addition of bone in the periosteum takes place
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phytes at the joint margin are created in a process resem-
bling endochondral ossification (Figure 6). A comparison
of the present data to the proteoglycan-induced arthritis
(PGIA) model reveals a high degree of similarity concern-
ing the mixed anabolic and catabolic bone remodelling
profile [8]. In contrast, the TNFα-transgenic arthritis
mouse model showed a primarily catabolic bone remod-
elling profile, while genes representing the osteoproli-
ferative response showed no or marginally differential
expression [7]. This is in line with a general comprehen-
sion of the TNFα-transgenic mouse as a mainly erosive
model, while the PGIA and CIA models demonstrate
osteoproliferative arthritis. All three models showed a
strong up-regulation of Mmps and Timp1. Data are com-
pared in Table S10 Additional file 10.
Highly differentially expressed genes encoding proteins
involved in bone formation between day 0 to 3 of clinical
arthritis are potential links between inflammation and bone
formation. Two of these genes are the insulin-like growthFigure 6 Bone remodelling in the CIA model. Model of bone remodellin
process in the bone is shown in the top part of the figure. Differentially ex
are divided into groups according to function and time point of highest diffe
in comparison to the control at the indicated time-point. Group 1: genes enc
2: genes encoding proteins with a function in extracellular matrix formation a
Group 3: genes encoding proteins with a function in extracellular matrix f
expression on day 0 to 4 and week 1 to 2); Group 4: genes with a function
to 2); Group 5: genes with a function in mineralisation of bone (highest di
arthritis; ECM, extracellular matrix.factor (IGF)-dependent proteinase pregnancy-associated
plasma protein A gene (Pappa) and periostin (Postn). In
addition, genes particularly involved in early ECM forma-
tion, preceding bone formation, are potential candidates.
The PAPP-A protein is an anabolic growth factor in bone
in vivo and in vitro [48,49] and regulates bioavailability of
Insulin-like growth factor (IGF) involved in bone formation
[50], and also differentially expressed. Expression of Pappa
is stimulated by inflammatory cytokines in several cell
types, including OBs, and macrophages isolated from
artherosclerotic lesions [51,52]. It has recently been identi-
fied as a marker of inflammation in acute coronary syn-
drome [53]. Furthermore, Pappa knockout mice display
disturbed bone formation [54,55], while mice overexpress-
ing Pappa have increased bone formation [48,49]. Thus,
Pappa expression might be induced in the early inflamma-
tory environment and the protein could be involved in ini-
tiating bone formation in the CIA model.
The Postn gene is one of the highly differentially
expressed genes with a proposed role in bone remodelling.g during the course of clinical arthritis. The proposed dominating
pressed genes, encoding proteins with a function in bone remodelling,
rential expression in comparison to the control. All genes are upregulated
oding proteins involved in osteoclast function and differentiation; Group
nd collagen type I assembly (highest differential expression at day 0 to 4);
ormation and collagen type I assembly (sustained high differential
in mineralisation of bone (highest differential expression in week 1
fferential expression during week 3 to 4). CIA, collagen-induced
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expressed during fracture repair, mechanical stress, and in
RA [14]. The expression is regulated by BMP2 and TGFβ.
Overexpression of periostin increases bone formation pos-
sibly by promoting cell survival of preosteoblasts and OBs
[56]. By binding fibronectin, tenascin and BMP1, it in-
creases the activation of pro-lysyl oxidase, which in turn
cross-links collagen [14]. Moreover, BMP1 has been linked
to arthritis and bone formation [57,58] and may increase
bone formation in several ways.
In weeks 1 to 2 after clinical onset, many genes reflect-
ing the mineralisation of osteoid showed the highest dif-
ferential expression over time in comparison to control
(Table 2 and Figure 4B). Integrin-binding sialoprotein
(Ibsp) is involved in the formation of crystals, as well as cell
attachment to hydroxyapatite [20]. Osteonectin (Sparc)
binds and connects hydroxyapatite to collagen type I [21],
while osteonectin (Spp1) binds hydroxyapatite crystals,
inhibiting their formation [21]. Moreover, these genes also
reflect the complexity of interactions between ECM,
OCs and OBs, as many of them have dual functions in
bone remodelling.
In summary, the network of regulated genes involved
in collagen type I assembly represented in Figure 4A,
might play an important role in arthritis-associated
ECM formation, leading to fibrosis and osteophyte
formation.
Of particular interest in arthritis-associated bone re-
modelling are molecules belonging to the BMP and WNT
signalling pathways. In human arthritis, the BMP ligands
2 and 6 [59] and their receptors BMPR1a and BMPR2
[60] were upregulated, while BMP ligands 4 and 5 were
downregulated in RA and osteoarthritis (OA) synovium
in comparison to normal control samples. Our results
showed a similar up-regulation of the genes for the re-
ceptors BMPR1a and BMPR2, but down-regulation of
Bmp4, Bmp6 and Bmp7 (Figure 5).
One of the strongly upregulated genes in this study is
Inhba (Inhibin beta A), which may stimulate the TGFβ
signalling pathway through binding to receptors Acv1b,
Avr2a and Avr2b. This non-steroidal hormone regulating
follicle-stimulating hormone (FSH) secretion is reported to
increase bone formation in a knock-in transgenic mouse
[61], and has been associated with human arthritis [62].
A profile of WNT signalling is not distinct in our gene
expression data, since most of the genes belonging to
this pathway were marginally differentially expressed com-
pared to the control samples. However, a number of WNT
inhibitors were differentially expressed. These included the
upregulated Hif1a. The encoded protein is a hypoxia indu-
cible factor that plays a role in angiogenesis during endo-
chondral bone formation. Together with Sp7, it inhibits
the WNT signalling pathway [63]. Moreover, WNT inhibi-
tors Sost and Ndgr2 were both downregulated and Dkk1,the master regulator of WNT signalling, was slightly down-
regulated. This could be expected during anabolic bone
conditions. Sost and Dkk1 downregulation has been associ-
ated with proteoglycan-induced arthritis in mice, and
DKK1 with human AS [8].
In Table 3, several genes identified in GWAS of hu-
man arthritis are listed together with the expression data
from the CIA model found in the present study. The five
underlined genes encode proteins with a function in car-
tilage or bone remodelling, and are potential therapeutic
candidate genes. The expression of those genes highlights
the importance of the CIA model for studies of osteoproli-
ferative inflammatory arthritic diseases.Conclusions
Bone remodelling in the CIA model results in ankylosis
within one to two weeks after clinical disease onset and
occurs simultaneously with the local inflammatory process
in the joint. Furthermore, in this study, we have identified
networks of genes involved in early and late bone forma-
tion, as well as genes associated with human arthritis,
which may provide potential targets for modulating bone
formation in arthritis.
Taken together, this suggests that the CIA model is an
important tool in investigations of the relationship be-
tween inflammation and bone formation in the search
for therapeutic targets to prevent ankylosis in inflamma-
tory arthritis.Additional files
Additional file 1: Table S2. A and B: Overview of samples used for
histology and global gene expression study.
Additional file 2: Figure S1. Illustration of histological bone scores.
(A) Bone erosion and formation score 0: no pathological changes.
(B) Bone erosion score 2. (C) Bone formation score 2. (D) Bone erosion
score 4. (E) Bone formation score 4.
Additional file 3: RMA gene default summary of array data for
review.
Additional file 4: Table S4. Table of assay IDs for specific primer/probe
sets (Life Techologies) used for validation of gene expression at AROS
Applied Biotechnology A/S.
Additional file 5: Table S5. (A) Comparison of samples from day 0 to 3
versus control. (B) Comparison of samples from week 1 to 2 versus control.
C) Comparison of samples from week 3 to 4 versus control. (D) Comparison
of samples from the declining disease phase versus control.
Additional file 6: Figure S6. Validation of selected genes by qPCR
showing correlation between the microarray data (X-axis, log2-transformed
values) and the qPCR data (Y-axis, δCt values). δCt,gene is calculated as Ct,
Gapdh-Ct,gene. Color coding, Red: day 0 to 3; Yellow: week 1 to 2; Green: week
3 to 4; Blue: declining disease phase; Black: control.
Additional file 7: Figure S7. Validation of selected genes by qPCR
showing a non-significant correlation between the microarray data
(X-axis, log2 transformed values) and the qPCR data (Y-axis, δCt values).
δCt,gene is calculated as Ct,Gapdh-Ct,gene. Color coding, Red: day 0 to 3;
Yellow: week 1 to 2; Green: week 3 to 4; Blue: declining disease phase;
Black: control.
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correlation between microarray and qPCR data.
Additional file 9: Table S9. Selected Bio Functions related to bone.
The Bio Functions that form the basis of the list of genes encoding
proteins with a function in bone remodelling.
Additional file 10: Table S10. List of genes encoding proteins with a
suggested function in bone remodelling. The list was created from data
in the selected Bio Functions and supplemented with genes based on
literature search. The data are also compared to data from other gene
expression studies. A list of references is available (please contact the
corresponding author).
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